Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype

Cancer Research

Volumn 58, Issue 18, 1998, Pages 4173-4179

  Bloomfield, Clara D ^a   Lawrence, David ^b   Byrd, John C ^c   Carroll, Andrew ^d   Pettenati, Mark J ^e   Tantravahi, Ramana ^f   Patil, Shivanand R ^g   Davey, Frederick R ^h   Berg, Deborah T ^f   Schiffer, Charles A ⁱ   Arthur, Diane C ^j   Mayer, Robert J ^f  

^a OHIO STATE UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CYTOGENETICS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; COHORT STUDIES; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 17544388046     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Arthur, D. C., Berger, R., Golomb, H. M., Swansbury, G. J., Reeves, B. R., Alimena, G., Van Den Berghe, H., Bloomfield, C. D., de la Chapelle, A., Dewald, G. W., Garson, O. M., Hagemeijer, A., Kaneko, Y., Mitelman, F., Pierre, R. V., Ruutu, T., Sakurai, M., Lawler, S. D., and Rowley, J. D. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet. Cytogenet., 40: 203-216, 1989.
2. Dastugue, N., Payen, C., Lafage-Pochitaloff, M., Bernard, P., Leroux, D., Huguet-Rigal, F., Stoppa, A-M., Marit, G., Molina, L., Michallet, M., Maraninchi, D., Attal, M., and Reiffers, J. Prognostic significance of karyotype in de novo adult acute myelogenous leukemia. Leukemia (Baltimore), 9: 1491-1498, 1995.
3. Stasi, R., Del Poeta, G., Masi, M., Tribalto, M., Venditti, A., Papa, G., Nicoletti, B., Vernole, P., Tedeschi, B., Delaroche, I., Mingarelli, R., and Dallapiccola, B. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet. Cytogenet., 167: 28-34, 1993.
4. Schiffer, C. A., Lee, E. J., Tomiyasu, T., Wiernik, P., and Testa, J. R. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood, 73: 263-270, 1989.
5. Mrózek, K., Heinonen, K., de la Chapelle, A., and Bloomfield, C. D. Clinical significance of cytogenetics in acute myeloid leukemia. Semin. Oncol., 24: 17-31, 1997.
6. Larson, R. A., Williams, S. F., Le Beau, M. M., Bitter, M. A., Vardiman, J. W., and Rowley, J. D. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood, 68: 1242-1249, 1986.
7. Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., and Ohki, M. The t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia clustered within a limited region of a novel gene AML1. Proc. Natl. Acad. Sci. USA, 88: 10431-10434, 1991.
8. Liu, P., Tarle, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., and Collins, F. S. Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia. Science (Washington DC), 261: 1041-1044, 1993.
9. van der Reijden, B. A., Bloomfield, C. D., Touw, I. P., and Jansen, J. H. Acute leukemias with structurally altered core binding factor subunits (t(8;;21), inv(16), t(12;22)). Leukemia (Baltimore), 11: 2217-2219, 1997.
10. Skipper, H. E., Schaebel, F. M., Jr., and Wilcox, W. S. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "cur-ability" of experimental leukemia. Cancer Chemother. Rep., 35: 1-11, 1964.
11. Champlin, R., Gajewski, J., Nimer, S., Vollset, S., Landaw, E., Winston, D., Schiller, G., and Ho, W. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J. Clin. Oncol., 7: 1199-1206, 1990.
12. Wolff, S. N., Herzig, R. H., Fay, J. W., Phillips, G. L., Lazarus, H. M., Flexner, J. M., Stein, R. S., Greer, J. P., Cooper, B., and Herzig, G. P. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J. Clin. Oncol., 7: 1260-1267, 1989.
13. Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., and Frei, E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med., 331: 896-903, 1994.
14. Bishop, J. F., Matthews, J. P., Young, G. A., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M. M., Fox, R., Cobcroft, R., Herrmann, R., Van Der Weyden, M., Lowenthal, R. M., Page, F., Garson, O. M., and Juneja, S. A randomized study of high-dose cytarabine in induction of acute leukemia. Blood, 87: 1710-1717, 1996.
15. Weick, J. K., Kopecky, K. J., Appelbaum, F. R., Head, D. R., Kingsbury, L. L., Balcerzak, S. P., Bickers, J. N., Hynes, H. E., Welborn, J. L., Simon, S. R., and Grever, M. R. A randomized investigation of high-dose versus standard-dose 1-β-D-arabinofuranosylcytosine with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 88: 2841-2851, 1996.
16. Büchner, T., Hiddemann, W., Löffler, G., Gassmann, W., Maschmeyer, G., Heit, W., Hossfeld, D., Weh, H., Ludwig, W. D., Thiel, E., Nowrousian, M., Aul, C., Lengfelder, E., Lathan, B., Mainzer, K., Urbanitz, D., Emmerich, B., Middelhoff, G., Donhuijsen-Ant, H. R., Hellriegel, H. P., and Heinecke, A. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML cooperative group. Semin. Hematol., 28: 76-79, 1991.
17. Zittoun, R. A., Mandelli, F., Willemze, R., Witte, T. D., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G., Papa, G., Caronia, F., Hayat, M., Stryckmann, P., Rotoli, B., Leoni, P., Peetermans, M. E., Dardenne, M., Vegna, M. L., Petti, M. C., Solbu, G., and Suciu, S. Autologous or allogeneic bone marrow transplant compared with intensive chemotherapy in acute myeloid leukemia. N. Engl. J. Med., 332: 217-223, 1995.
18. Harousseau, J. L., Cahn, J. Y., Pignon, B., Witz, F., Delain, M., Lioure, B., Lamy, T., Desablens, B., Briere, J., Cassasus, P., Audhuy, B., Polin, V., Tellier, Z., and Hurteloup, P. Autologous bone marrow transplantation versus intensive consolidation chemotherapy as post-remission therapy in adult acute myeloblastic leukemia: final analysis of the Goelamm randomized study. Proc. Am. Soc. Clin. Oncol., 15: 358, 1996.
19. Cassileth, P., Harrington, D., Paietta, E., Lazarus, H., Appelbaum, F., Bennett, K. J., Hurd, D., Willman, C., Magenis, E., and Wiernik, P. Comparison of autologous bone marrow transplant with high-dose cytarabine in acute myeloid leukemia in first remission: an ECOG intergroup study. Proc. Am. Soc. Clin. Oncol., 16: 89, 1997.
20. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., and Sultan, C. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann. Intern. Med., 103: 626-629, 1985.
21. ISCN. An International System for Human Cytogenetic Nomenclature. Basel: S. Karger, 1995.
22. Cheson, B. D., Cassileth, P. A., Head, D. R., Schiffer, C. A., Bennett, J. M., Bloomfield, C. D., Brunning, R., Gale, R. P., Grever, M. R., Keating, M. J., Sawitsky, A., Stass, S., Weinstein, H., and Woods, W. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myelogenous leukemia. J. Clin. Oncol., 8: 813-819, 1990.
23. Tarone, R. E., and Ware, J. On distribution-free tests for equality of survival distributions. Biometrika, 64: 156-160, 1977.
24. Maller, R. A., and Zhou, S. Estimating the proportion of immune in a censored sample. Biometrika, 79: 731-739, 1992.
25. Goldman, A. Survivorship analysis when cure is a possibility: a Monte Carlo study. Stat. Med., 3: 153-163, 1984.
26. Farewell, V. T. The use of mixture models for the analysis of survival data with long-term survivors. Biometrics, 38: 1041-1046, 1982.
27. Farewell, V. T. A model for a binary variable with time-censored observations. Biometrika, 64: 43-46, 1977.
28. Lawless, J. F. Statistical Models and Method for Lifetime Data. New York: John Wiley and Sons, 1982.
29. Halpern, J., and Brown, B. W. Cure rate models: power of the logrank and generalized Wilcoxon tests. Stat. Med., 6: 483-489, 1987.
30. Moore, J. O., Dodge, R. K., Amrein, P. C., Kolitz, J., George, S., Dodge, R., Rizzieri, D. A., and Schiffer, C. A. Granulocyte-colony stimulating factor accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood, 89: 780-788, 1997.
31. Cuneo, A., Ferrant, A., Michaux, J. L., Boogaerts, M., Demuynck, H., Van Orshoven, A., Criel, A., Stul, M., Cin, P. D., Hernandez, J., Chatelein, B., Doyen, C., Louwagie, A., Castoldi, G., Cassiman, J. J., and Van Den Berghe, H. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood, 85: 3688-3694, 1995.
32. Stasi, R., Del Poeta, G., Venditti, A., Masi, M., Stipa, R., Dentamaro, T., Cox, C., Dallapiccola, B., and Papa, G. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood, 83: 1619-1625, 1994.
33. Rowley, J. D., Alimena, G., Garson, O. M., Hagemeijer, A., Mitelman, F., and Prigogina, E. L. Collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. Blood, 59: 1013-1022, 1982.
34. Tricot, G., Orshoven, B. V., Daele, C. V., and Van Den Berghe, H. 8;21 translocation in acute myeloid leukaemia. Scand. J. Haematol., 26: 168-176, 1981.
35. Groupe Francais de Cytogenetique Hematologique. Acute myelogenous leukemia with an 8;21 translocation. Cancer Genet. Cytogenet., 44: 169-179, 1990.
36. Davey, D. D., Patil, S. R., Echternacht, H., Fatemi, C., and Dick, F. R. 8;21 translocation in acute nonlymphocytic leukemia. Am. J. Clin. Pathol., 92: 172-176, 1989.
37. Marlton, P., Keating, M., Kantarjian, H., Pierce, S., O'Brien, S., Freireich, E. J., and Estey, E. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia (Baltimore), 9: 965-971, 1995.
38. Ghaddar, H. M., Plunkett, W., Kantarjian, H. M., Pierce, S., Freireich, E. J., Keating, M. J., and Estey, E. H. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose 1-β-D-arabinofuranosylcytosine. Leukemia (Baltimore), 8: 1269-1274, 1994.
39. Caligiuri, M. A., Strout, M. P., Lawrence, D., Arthur, D. C., Baer, M. R., Yu, F., Knuutila, S., Mrózek, K., Oberkircher, A. R., Marcucci, G., de la Chapelle, A., Elonen, E., Block, A. W., Rao, P. N., Herzig, G. P., Powell, B. L., Ruutu, T., Schiffer, C. A., and Bloomfield, C. D. Rearrangement of ALLI (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res., 58: 55-59, 1998.